Full-Time

Associate Director

Clinical Development, Cardiometabolic Health

Posted on 8/12/2025

Lilly USA

Lilly USA

10,001+ employees

Global pharmaceutical company developing medicines

No salary listed

Cork, Ireland

Hybrid

Flexible hybrid working options available.

Category
Medical, Clinical & Veterinary (1)
Required Skills
Risk Management
Data Analysis
Google Cloud Platform
Requirements
  • Bachelors or University degree (scientific or health-related field preferred) and 5 years clinical research experience or relevant experience in a scientific or health-related field; or an advanced degree.
  • Minimum of 5 years clinical trial experience with a strong working knowledge of the clinical research process.
Responsibilities
  • Partners with functional, cross-functional and team leadership to provide operational input into the feasibility and resource requirements associated with clinical plans.
  • Provides strategic direction and leadership to CTPMs to enable them to drive the implementation of the Regional/Global enrollment strategy, to accomplish milestones to plan. Escalates related issues to appropriate parties for awareness and resolution.
  • Collaborates with Medical Sourcing, Procurement, CPM, and compound Team Management to provide and enable decisions related to internal/external-sourcing options.
  • Works closely with the clinical project manager to ensure planning databases are accurate and up-to-date.
  • Works to align resources based upon team prioritization decisions and regional participation in the trial.
  • Manages study management personnel workload based on portfolio, global and regional requirements and expertise level of the individual.
  • Facilitates discussions within functional counterparts to manage team priorities and address unplanned demands.
  • Recruit, retain and develop top talent to ensure a high performing team culture.
  • Facilitates problem-solving, shared learning and decision-making across clinical functions.
  • Participates in risk assessments at the clinical plan level and ensures development and implementation of cross-functional risk management plans at the trial level.
  • Ensures inspection readiness of respective study team(s). Oversees and coaches CTPMs in the timely documentation of deviations, creation of story boards or issue summary documents (e.g. for high risk areas/hot topics).
  • Oversees and provides direction in obtaining appropriate personnel involvement as compliance issues are identified which require further action or follow-up.
  • Has shared responsibility with training group to ensure that curriculum maps and training programs/courses are maintained appropriately for staff members to enable them to perform their job responsibilities. Consults as appropriate on new training programs/courses.
  • Ensures that team members adhere to and complete trainings related to GCPs, global SOPs, and clinical best practices.
  • Evaluates CTPMs capabilities and behaviors, aids in directly coaching or identifies appropriate coaches for consultants, associates and assistants to enable them to become proficient in completion of study responsibilities.
  • Monitors training compliance for consultants, associates and assistants ensuring timely completion of all required courses.
  • Ensures quality in clinical research activities by promoting consistent use of GCPs, global SOPs, and best practices.
  • Generates innovative ideas, leads and/or provides input into new processes and process improvements within the clinical organization to enhance productivity and quality.
  • Actively supports staff to share any new learning opportunities or technologies within or across clinical functions.
  • Encourages staff to utilize metrics data in order to assess the current status of the clinical program, to monitor progress, and to seek opportunities for improvement over time.
  • Participates in reviewing and implementing new clinical trial processes within teams. Assesses the impact of these changes in achieving specific project team goals.
  • Partners with other cross-functional leadership in identifying and facilitating resolution of clinical trial operational issues.
  • Facilitates high-level discussions with vendors, as appropriate.
  • Manages the Performance Management process for staff members by providing input in yearly objectives, reviewing progress, and providing timely and objective feedback and completing appropriate documentation.
  • Completes salary administration for reporting staff members.
  • Completes talent assessment and succession planning for direct reports, and discusses results with individual staff members maintaining the integrity and privacy of the data.
Desired Qualifications
  • Demonstrated technical and process expertise in clinical trial development. Must understand the drug development process and interdependencies of various tasks and functional groups.
  • Strong communication skills. Communicates effectively up and down in an organization and maintains confidentiality with respect to strategic and personnel matters.
  • Proven ability to coach others.
  • Strong people and leadership skills with demonstrated ability to influence and lead across clinical functions.
  • Strong interpersonal, teamwork, and negotiation skills.
  • Strong self-management and organizational skills.
  • Must be capable of managing staff virtually and across-borders and cultures, demonstrating an understanding of cultural differences.
  • Previous supervisory experience.
  • Global clinical trial experience.
  • Prior experience with the management of business plans.
  • Demonstrated strong business skills including the ability to understand and facilitate planning processes across clinical functions.

Lilly is a global pharmaceutical company that discovers, develops, and sells prescription medicines to improve health outcomes. It grows its portfolio through extensive research and development, then manufactures and distributes drugs worldwide to healthcare providers who prescribe them to patients. Lilly’s products span diabetes, cancer, immunology, pain management, and other serious conditions, including diabetes treatments tirzepatide and dulaglutide. The company emphasizes safety, efficacy, and ethical practices, and protects its products from counterfeiting while partnering with organizations such as Team USA. Its approach relies on rigorous R&D, strong manufacturing, and a global distribution network to bring medicines to patients. Lilly’s goal is to help people live better lives by delivering reliable medical solutions through a global, ethical, and quality-focused operation.

Company Size

10,001+

Company Stage

IPO

Headquarters

Indianapolis, Indiana

Founded

1876

Simplify Jobs

Simplify's Take

What believers are saying

  • International Mounjaro sales jumped to $4.4 billion in Q1 from China's reimbursement list.
  • $4.5 billion Lebanon API plant opens 2027, producing tirzepatide and retatrutide at largest scale.
  • Acquires Scorpion's PI3Kα inhibitor, bolstering oncology pipeline beyond Verzenio.

What critics are saying

  • Novo Nordisk's Wegovy scaling erodes Lilly's US GLP-1 share below 25% into 2027.
  • FDA scrutiny delays Foundayo launch after May 4 hepatic failure, losing $2-3B Q4 revenue.
  • Shareholder demands force independent board chair, dropping stock 10-15% in 12 months.

What makes Lilly USA unique

  • Mounjaro generated $8.66 billion in Q1 2026 sales, surpassing Keytruda as world's best-selling drug.
  • Launched first genetic medicine facility in Lebanon on May 6, 2026, for Alzheimer's and ALS.
  • Partnered with Profluent Bio for up to $2.25 billion AI-driven DNA editing tools on May 5.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Flexible Work Hours

Wellness Program

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

-4%

2 year growth

-4%
The Lebanon Reporter
May 7th, 2026
Lilly invests additional $4.5B in LEAP district, opens first genetic medicine facility

Eli Lilly has announced an additional $4.5 billion investment in its Lebanon, Indiana facilities, bringing its total investment in the LEAP Innovation and Research district to $21 billion. The company opened its first Advanced Therapies site on Wednesday, marking the first operational facility in the 9,000-acre LEAP district. The new funding will support Lilly's Advanced Therapies laboratory and an active pharmaceutical ingredient facility expected to open in 2027. The Advanced Therapies site is Lilly's first dedicated genetic medicine manufacturing facility, focusing on molecular-level research for diseases including Alzheimer's, Parkinson's and ALS. Lilly is developing three facilities across 800 acres in LEAP, including a Medicine Foundry. The Advanced Therapies facility aims to accelerate delivery of breakthrough genetic medicines to patients.

AI Software Services
May 5th, 2026
Unlocking AI innovation in finance medicine and music.

Unlocking AI innovation in finance medicine and music. Published on May 05, 2026 GENETIC MEDICINE REVOLUTION: AI AND BIOTECH JOIN FORCES. In a groundbreaking partnership, Lilly and AI-driven Profluent Bio are teaming up in a deal worth up to $2.25 billion to develop advanced DNA editing tools. Their goal? To create precise treatments for genetic conditions that currently lack effective solutions, using innovative AI models to design enzymes that can target multiple mutations in the genome. This collaboration aims to unlock the "holy grail" of genetic medicine through kilobase-scale DNA editing. This matters because it could transform how AI Software Services treat genetic diseases, offering hope to millions who suffer from conditions deemed untreatable. The tools being developed are likely to be accessible, lowering barriers to entry in a field that has traditionally been expensive and exclusive. Imagine a startup that provides a platform for creators and developers to access these AI-driven genetic editing tools, enabling them to innovate and create personalized therapies. This could attract investors eager to support the next wave of medical breakthroughs!

The Economic Times
May 4th, 2026
French fines over anti-obesity adverts for Novo Nordisk, Eli Lilly.

French fines over anti-obesity adverts for Novo Nordisk, Eli Lilly. The ANSM fined Novo Nordisk 783,838 euros regarding adverts for Wegovy and also fined Lilly France 108,766 euros for a campaign promoting its anti-obesity drug Mounjaro, seeing the adverts as "likely to constitute indirect promotion of medicines subject to mandatory medical prescription." * Updated On May 4, 2026 at 05:54 PM IST Paris: France's medicine safety agency ANSM said Monday it had imposed fines on pharmaceutical firms Novo Nordisk and Eli Lilly over their advertising campaigns on obesity. The agency fined on Novo Nordisk France 1.78 million euros ($2.08 million) - a million relating to adverts promoting its Saxenda drug and 783,838 euros regarding adverts for Wegovy weight management medication for treating obesity. The ANSM also fined Lilly France 108,766 euros for a campaign promoting its anti-obesity drug Mounjaro, seeing the adverts as "likely to constitute indirect promotion of medicines subject to mandatory medical prescription." French laws prohibit any advertising to the general public of the treatments. The national medicines regulator said that the fines aimed to "prevent any communication likely to promote the use of drug treatment as the principal response to obesity, to encourage the public to request this treatment from a healthcare professional or seek to obtain it themselves." Event. * Fri, 24 Jul 2026 * Le Meridien, Hyderabad The ANSM said the advertising campaigns were "likely to mislead the public in a context marked by extensive media coverage" as well as what it termed growing inappropriate use of medications which activate certain hormones in order notably to reduce appetite,and aid weight loss. In a statement to AFP, Novo Nordisk France said it "strongly contests" the ANSM's finding, adding it is "exploring all possible appeal avenues against this decision". Lilly France said it noted ANSM's decision, while stating it believes its awareness campaign entitled "Obesity is a sick person's problem" from a year ago was "in line with the framework applicable to communications relating to human health". According to a French study published in 2024, around 18 percent of the French population - equivalent to some ten million people - are obese.

NBC News
Apr 14th, 2026
FDA requests more safety data from Lilly on weight loss pill Foundayo

The FDA is requesting additional safety data from Eli Lilly for its weight loss pill Foundayo, including information on potential heart and liver problems, according to the approval letter published Tuesday. The agency wants more data on risks including heart attacks, strokes, drug-induced liver injuries and delayed stomach emptying. Foundayo, approved this month under a fast-track pilot programme, is the second oral GLP-1 to reach market after Novo Nordisk's Wegovy pill. The FDA is also asking Lilly to collect thyroid cancer risk data for at least 15 years. The requests are considered routine for newly approved drugs, particularly for orforglipron, Foundayo's active ingredient, which has less safety data than older GLP-1s. Lilly must also establish registries tracking children with obesity and pregnancy outcomes.

PR Newswire
Apr 14th, 2026
Vasa Therapeutics partners with Lilly TuneLab to accelerate AI-driven CAMKII inhibitor development

Vasa Therapeutics, a clinical-stage biopharmaceutical company, has partnered with Eli Lilly to use Lilly TuneLab, an AI-enabled drug discovery platform that provides access to models trained on Lilly's proprietary research data. Vasa will use the platform to accelerate development of its CAMKII delta inhibitor, which is planned for Phase 1 clinical trials in 2027. The company's VS-041 is currently in a proof-of-mechanism trial for heart failure, whilst VS-214 is on track for first-in-human trials in 2026. The platform uses federated learning, allowing companies to access Lilly's AI models whilst maintaining data privacy. Vasa will contribute its own experimental datasets to support the platform's improvement. The company focuses on developing therapies for cardiovascular, neuromuscular and age-related disorders.

INACTIVE